SPRY - רווח נקי למניה (EPS TTM) ARS Pharmaceuticals Inc

The growth foundation of ARS Pharmaceuticals (SPRY) is based on the creation of Neffy, the first painless alternative to injections for anaphylaxis. This rolling annual EPS chart confirms this potential, where -2.02 represents the current level of the metric. This breakthrough in emergency medicine is complemented by a stable staff of scientists and targeted reinforcement of the commercial division, ensuring confident business development.

This indicator measures the company's aggregate net income distributed per common share over the last four quarters, allowing for an assessment of actual profit generation efficiency. For ARS Pharmaceuticals (SPRY), the rolling year net income per share trend verifies the commercial success of the neffy spray, confirming the transition from development to revenue scaling and the strengthening of market positions.